Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium leprae | PROBABLE REPLICATIVE DNA HELICASE DNAB replicative DNA helicase | 0.0662 | 0.5 | 0.5 |
Mycobacterium ulcerans | replicative DNA helicase DnaB | 0.0662 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Probable replicative DNA helicase DnaB | 0.0662 | 0.5 | 0.5 |
Schistosoma mansoni | Replicative DNA helicase | 0.0662 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | replicative DNA helicase | 0.0662 | 0.5 | 0.5 |
Treponema pallidum | replicative DNA helicase (dnaB) | 0.0662 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | Transactivation of PPARgamma (unknown origin) expressed in HEK293 cells incubated for 24 hrs by luciferase reporter gene assay relative to rosiglitazone | ChEMBL. | 25442322 | |
Activity (functional) | = 81.02 % | Anticancer activity against human HOP62 cells assessed as cell growth level at 10 uM after 48 hrs by sulforhodamine B assay | ChEMBL. | 25442322 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.